Humacyte, Inc.
HUMA
$3.13
$0.123.99%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -12.89% | -96.57% | |||
| Gross Profit | 12.89% | 96.57% | |||
| SG&A Expenses | 27.17% | 8.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.49% | 10.99% | |||
| Operating Income | -2.49% | -10.99% | |||
| Income Before Tax | 30.82% | -77.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.82% | -77.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.82% | -77.65% | |||
| EBIT | -2.49% | -10.99% | |||
| EBITDA | -2.53% | -11.83% | |||
| EPS Basic | 30.96% | -61.35% | |||
| Normalized Basic EPS | 1.41% | -3.49% | |||
| EPS Diluted | 30.96% | -61.35% | |||
| Normalized Diluted EPS | 1.41% | -3.49% | |||
| Average Basic Shares Outstanding | 0.20% | 10.10% | |||
| Average Diluted Shares Outstanding | 0.20% | 10.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
